news
Antibodies from recovered COVID-19 patients inhibit SARS-CoV-2 infection in cells
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
List view / Grid view
Antibodies
news
Why do some patients develop COVID-19 pneumonia?
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
whitepaper
Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
whitepaper
On-demand webinar: Exploring absorbance-based assay applications: From virus to cannabis research
Discover how absorbance detection works as well as different types of absorbance-based assay applications that scientists can utilise for their research.
whitepaper
Article: Imaging dataset for COVID-19 research
Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research.
news
Tiny antibody component could treat or prevent SARS-CoV-2
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
article
Expert view: Measuring protein interactions in blood – not as trivial as it sounds
In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.
whitepaper
Application note: Accurate affinity profiling of a SARS-CoV-2 antibody in serum
In this application note, Fluidic Analytics show that by using MDS on the Fluidity One-W Serum we can accurately detect and characterise the binding affinity of antibodies to virus proteins directly in human serum.
article
Bispecific antibodies: the next generation of immuno-oncology drugs
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
article
Oncology meets immunology – antibody-mediated regulation of the immune response
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Defusing antibody neutralisers in AAV gene therapy
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
article
Expert view: Analytical power tool opens upstream bioprocessing bottlenecks for better antibody screening
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
article
Expert view: Increasing the efficiency of biologics development: the secret is precise and reliable stability characterisation of candidate molecules
Biologics are becoming increasingly important for the treatment of a wide variety of diseases, with more biologics receiving regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and entering the clinic every year.
whitepaper
Application note: Validated quantitation and activity assay of antibody fragment molecule (Fab) for process development and quality control
This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.
